2022 Sep 6;13(11):3234-3243
However, scientists still have many unanswered questions
We know when we manage our patients with type 2 diabetes, we not only need to be concerned about glycemic control, but also about reducing cardiometabolic risk as well as weight reduction since most of our patients are overweight or obese, Juan P
Dual GLP-1 RA and glucagon agonists as well as Triple GLP-1/GIP/glucagon RA are still ongoing clinical evaluations but have shown significant reduction in HbA1c levels and weight management
The Legal Landscape Surrounding GLP-1 Medications Glucagon-like peptide-1 receptor agonists, commonly known as GLP-1 medications , were originally developed to manage type 2 diabetes
Following the intake of nutrients, the beginning of the incretin effect is marked by rising levels of active GLP-1 which promote the synthesis and release of insulin 1,2,4